Characterization, management and prognosis of a cohort of cirrhotic patients with hepatocellular carcinoma. Pablo Tobón Uribe Hospital 2012-2018

Authors

  • Juan Ignacio Marín-Zuluaga Hospital Pablo Tobón Uribe, Universidad Pontificia Bolivariana https://orcid.org/0000-0001-6954-8910
  • Juliana Vergara-Cadavid Harvard Medical School https://orcid.org/0000-0002-1137-8098
  • Liliana Cajiao-Castro Universidad de Antioquia
  • Danny Arroyave-Zuluaga Universidad Pontificia Bolivariana
  • Susana Castro-Sánchez Universidad de Antioquia
  • Laura Ceballos-Ramírez Hospital Pablo Tobón Uribe
  • Octavio Muñoz-Maya Hospital Pablo Tobón Uribe, Universidad de Antioquia https://orcid.org/0000-0002-5712-2864
  • Gabriel Sebastián Díaz-Ramírez Fundación Valle del Lili, Universidad del Valle

DOI:

https://doi.org/10.52784/27112330.121

Keywords:

hepatocellular carcinoma, liver cirrhosis, survival, therapeutics, liver transplantation.

Abstract

Introduction. Hepatocellular carcinoma (HCC) in patients with liver cirrhosis is a frequent indication for liver transplantation and a cause of death if not diagnosed promptly. The aim of this study was to describe the demographics, and clinical and laboratory characteristics of patients with HCC in a cirrhotic liver, as well as the stage at the time of diagnosis, type of treatment offered, and survival, according to BCLC classification. Methodology. Retrospective observational cohort study, which included patients treated at a center in Colombia between January 1 2012 and December 31 2018, aged ≥18 years, with hepatocarcinoma. Information was collected from medical records. Collected data was analyzed using SPSS 23.0. Results. We included 219 patients with HCC and underlying liver cirrhosis. Males were 58.9% and median age was 65 years. Etiological distribution of cirrhosis for alcohol, non-alcoholic steatohepatitis (NASH), cryptogenic, and hepatitis B and C viral infection was 30.6%, 21.4%, 19.1%, 12.2% and 7.7%, respectively. At diagnosis, 49.3% had Child-Pugh A score, 37% B and 13.7% C. BCLC classification was distributed as follows: 0=4 (1.8%), A=94 (42.9%), B=26 (11.9%), C=39 (17.8%) and D=56 (25.6%). Survival, according to BCLC classification, was for BCLC 0=60 months, A=84.6 months, B=28.7 months, C=10.7 months and for BCLC D=7 months. Conclusion. Despite finding better survival in this series, compared to that found in another series from our center in 2009, and similar to that reported worldwide, a delayed diagnosis continuesto be the main cause of mortality in patients with HCC.

Downloads

Download data is not yet available.

Author Biographies

Juan Ignacio Marín-Zuluaga, Hospital Pablo Tobón Uribe, Universidad Pontificia Bolivariana

Médico, Especialista en Medicina Interna, Especialista en Hepatología Clínica y Trasplante Hepático. Unidad de Hepatología y Trasplante Hepático, Hospital Pablo Tobón Uribe. Profesor, Universidad Pontificia Bolivariana. Medellín, Colombia.

Juliana Vergara-Cadavid, Harvard Medical School

Médica General, Universidad de Antioquia. Medellín, Colombia. Estudiante, MSc en Ciencias Médicas en Investigación Clínica, Harvard Medical School. Boston, Massachusetts, Estados Unidos.

Liliana Cajiao-Castro, Universidad de Antioquia

Médica General, Universidad de Antioquia. Medellín, Colombia.

Danny Arroyave-Zuluaga, Universidad Pontificia Bolivariana

Médico General, Universidad Pontificia Bolivariana. Medellín, Colombia.

Susana Castro-Sánchez, Universidad de Antioquia

Estudiante del VIII semestre de Medicina, Universidad de Antioquia. Medellín, Colombia.

Laura Ceballos-Ramírez, Hospital Pablo Tobón Uribe

Enfermera, Especialista en Cuidado al Adulto en Estado Crítico de Salud, Hospital Pablo Tobón Uribe. Medellín, Colombia.

Octavio Muñoz-Maya, Hospital Pablo Tobón Uribe, Universidad de Antioquia

Médico, Especialista en Medicina Interna, Especialista en Hepatología Clínica y Trasplante Hepático. Unidad de Hepatología y Trasplante Hepático, Hospital Pablo Tobón Uribe. Profesor Sección de Gastrohepatología, Universidad de Antioquia. Medellín, Colombia.

Gabriel Sebastián Díaz-Ramírez, Fundación Valle del Lili, Universidad del Valle

Médico, Especialista en Medicina Interna, Especialista en Hepatología Clínica. Unidad de Trasplante Hepático, Fundación Valle del Lili. Profesor, Departamento de Medicina Interna, Universidad del Valle. Cali, Colombia.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424. https://doi.org/10.3322/caac.21492.

Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391:1301-1314. https://doi.org/10.1016/S0140-6736(18)30010-2.

Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-338. https://doi.org/10.1055/s-2007-1007122.

Díaz LA, Barrera F. Clasificación Barcelona Clinic Liver Cancer (BCLC) de carcinoma hepatocelular. Gastroenterol Latinoam 2015;26:63-68.

Tellapuri S, Sutphin PD, Beg MS, Singal AG, Kalva SP. Staging systems of hepatocellular carcinoma: A review. Indian J Gastroenterol 2018;37:481-491. https://doi.org/10.1007/s12664-018-0915-0.

European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236. https://doi.org/10.1016/j.jhep.2018.03.019.

Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67:358-380. https://doi.org/10.1002/hep.29086.

Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005;41:707-716. https://doi.org/10.1002/hep.20636.

Liu PH, Hsu CY, Hsia CY, Lee YH, Su CW, Huang YH, et al. Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. J Hepatol 2016;64:601-608. https://doi.org/10.1016/j.jhep.2015.10.029.

Yao FY, Fidelman N. Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: Where do we stand with tumor down-staging? Hepatology 2016;63:1014-1025. https://doi.org/10.1002/hep.28139.

Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, Fix O, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology 2015;61:1968-1977. https://doi.org/10.1002/hep.27752.

Mehta N, Dodge JL, Grab JD, Yao FY. National experience on down-staging of hepatocellular carcinoma before liver transplant: Influence of tumor burden, alpha-fetoprotein, and wait time. Hepatology 2020;71:943-954. https://doi.org/10.1002/hep.30879.

Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390. https://doi.org/10.1056/NEJMoa0708857.

Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391:1163-1173. https://doi.org/10.1016/S0140-6736(18)30207-1.

Kudo M. Immuno-oncology therapy for hepatocellular carcinoma: Current status and ongoing trials. Liver Cancer 2019;8:221-238. https://doi.org/10.1159/000501501.

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020;382:1894-1905. https://doi.org/10.1056/NEJMoa1915745.

Hoyos S, Escobar J, Cardona D, Guzmán C, Mena Á, Osorio G, et al. Factors associated with recurrence and survival in liver transplant patients with HCC: a single center retrospective study. Ann Hepatol 2015;14:58-63. https://doi.org/10.1016/S1665-2681(19)30801-4.

Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007;147:W163-194. https://doi.org/10.7326/0003-4819-147-8-200710160-00010-w1.

Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 2019;16:589-604. https://doi.org/10.1038/s41575-019-0186-y.

Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 2015;35:2155-2166. https://doi.org/10.1111/liv.12818.

Goldberg D, Ditah IC, Saeian K, Lalehzari M, Aronsohn A, Gorospe EC, et al. Changes in the prevalence of hepatitis C virus infection, nonalcoholic steatohepatitis, and alcoholic liver disease among patients with cirrhosis or liver failure on the waitlist for liver transplantation. Gastroenterology 2017;152:1090-1099. https://doi.org/10.1053/j.gastro.2017.01.003.

Piscaglia F, Svegliati-Baroni G, Barchetti A, Pecorelli A, Marinelli S, Tiribelli C, et al. Clinical patterns of hepatocellular carcinoma in nonalcoholic fatty liver disease: A multicenter prospective study. Hepatology 2016;63:827-838. https://doi.org/10.1002/hep.28368.

Piñero F, Pages J, Marciano S, Fernández N, Silva J, Anders M, et al. Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina. World J Hepatol 2018;10:41-50. https://doi.org/10.4254/wjh.v10.i1.41.

Cisneros-Garza LE, González-Huezo MS, López-Cossio JA, Kuljacha-Gastelum AL. Characterization of hepatocellular carcinoma in Mexico. Rev Gastroenterol Mex (English edition) 2018;83:223-227. https://doi.org/https://doi.org/10.1016/j.rgmxen.2017.06.005.

Kanwal F, Singal AG. Surveillance for hepatocellular carcinoma: Current best practice and future direction. Gastroenterology 2019;157:54-64. https://doi.org/10.1053/j.gastro.2019.02.049.

Santa C, Ortiz MM, Hoyos S, Guzmán C, Mena A, Zuleta JJ, et al. Pronóstico de pacientes con diagnóstico de carcinoma hepatocelular (CHC) en un hospital de máximo nivel de atención. Rev Colomb Gastroenterol 2009;24:128-133.

Piñero F, Marciano S, Fernández N, Silva J, Anders M, Zerega A, et al. Intermediate-advanced hepatocellular carcinoma in Argentina: Treatment and survival analysis. World J Gastroenterol 2019;25:3607-3618. https://doi.org/10.3748/wjg.v25.i27.3607.

Piñero F, Marciano S, Fernández N, Silva J, Zambelo Y, Cobos M, et al. Adherence to Barcelona Clinic Liver Cancer therapeutic algorithm for hepatocellular carcinoma in the daily practice: a multicenter cohort study from Argentina. Eur J Gastroenterol Hepatol 2018;30:376-383. https://doi.org/10.1097/meg.0000000000001049.

Published

2020-07-19

How to Cite

Marín-Zuluaga, J. I., Vergara-Cadavid, J., Cajiao-Castro, L., Arroyave-Zuluaga, D., Castro-Sánchez, S., Ceballos-Ramírez, L., … Sebastián Díaz-Ramírez, G. (2020). Characterization, management and prognosis of a cohort of cirrhotic patients with hepatocellular carcinoma. Pablo Tobón Uribe Hospital 2012-2018. Hepatología, 1(2), 133–144. https://doi.org/10.52784/27112330.121

Issue

Section

Original articles
QR Code